NEWS | Innovation for Life

SINGAPORE, April 27, 2021 – Prestige Biopharma Limited, specializing in the development of antibody therapeutics, announced a strategic partnership with Cytiva on April 27, 2021. The signing ceremony was held at its affiliated company, Prestige Biologics in Osong, South Korea. Those attending included President and CEO of Cytiva Emmanuel Ligner, Vice President Commercial, Asia-Pacific of Cytiva Francis Van Parys, General Manager of Cytiva Korea Joon Ho Choi, Group Chairman and CEO of Prestige Biopharma Group Lisa Soyeon Park and Group Vice Chairman and COO of Prestige Biopharma Group Michael Jinwoo Kim.Through this partnership, Cytiva will supply bioprocessing equipment for cell culture and purification that will be used for vaccine and biologics production. Cytiva will also be providing technologies and solutions for bio-manufacturing to help Prestige Biopharma to rapidly produce multiple vaccines and biologics.Prestige Biopharma will be procuring a variety of bioprocessing equipment including 50 units of 2,000 litre single-use bioreactors and will be using them to produce Russia’s Sputnik V COVID-19 vaccine. Prestige Biopharma vaccine center’s test operation is expected to commence in August and aims to start full production of 100 million doses of vaccine DS (Drug Substance) per month from September this year.Cytiva Korea’s General Manager, Mr. Joon Ho Choi commented, “we are very excited to enter into this partnership that will build a global-scale supply chain” and “hopefully our partnership will enable Prestige Biopharma with further production capabilities to assist in defeating the pandemic”. “Cytiva will also support PBP’s antibody therapeutics business as well” added Mr. Choi.Dr. Lisa S. Park, CEO of Prestige Biopharma, commented: “Despite the current vaccine distribution, most of the global population unfortunately still lacks access to life-saving, essential COVID-19 vaccines and global vaccine developers are facing increasing challenges in rapidly building supply chains to meet the high demand,” and “with this novel partnership and our global-scale vaccine centre, PBP Group will contribute to the growing global demands of vaccine development and production in response to the current situation, and also for potential, viral pandemics of the future.”

SINGAPORE, April 20, 2021 – Prestige Biopharma Limited, specializing in the development of antibody therapeutics, announces that the company will be introducing a vaccine development and production center into its core business. Prestige Biopharma has been preparing for a business expansion into the development of vaccine-based therapeutics since the start of the ongoing COVID-19 outbreak as a response to the current, and potential future, viral pandemics. The design, development and implementation of the vaccine center has resulted from that plan.Prestige Biopharma is on target to complete the construction of its global-scale vaccine production facility in Osong, South Korea with a total area of approximately 8,500 m2 inside the Campus 2 facility of its affiliated company Prestige Biologics. The vaccine center initiated construction last month (March 2021) and is projected to start operations from August 2021 utilizing Prestige Biologics’ unmatched engineering service for expedited establishment with cutting-edge technology.Prestige Biopharma will be utilising Prestige Biologics’ proprietary ALITA Smart BioFactory™, the world’s first smart factory system in biomanufacturing designed based on digital artificial intelligence, which will contribute to reducing human or process related errors. The system will also enable fast and convenient change-over to maximize efficiency when catering for multiple products and manufacturing processes. This smart factory’s ‘single-use’ system will enable mass production of vaccine in the short-term.The total production capacity of the vaccine center is 100,000 litres, comprised of 50 units of 2,000 litre single-use bioreactors with accompanying seed train and down-stream purification capacities. With this global-scale production capacity, the center will contribute to the growing global demands of vaccine development and production in response to infectious diseases such as COVID-19.Prestige Biopharma will participate in a consortium led by Huons Global in the production of Russia’s Sputnik V COVID-19 vaccine as the Drug Substance (DS) manufacturing center.Dr. Lisa S. Park, CEO of Prestige BioPharma, commented: “The prolonged fight against the COVID-19 pandemic has led to growing concerns surrounding infectious viral disease and the increased necessity for production capability for vaccine-based therapeutics,” and “Hopefully our global-scale vaccine center will assist in defeating the pandemic and we will ultimately aim to develop our own vaccine products to combat potential future pandemics.” 

SINGAPORE, April 16, 2021 – Prestige Biopharma Limited, specializing in the development of antibody therapeutics, announced on April 16, 2021 that it has participated in a consortium that will be producing Russia’s Sputnik V COVID-19 vaccine. South Korean biotech firm Huons Global will lead the consortium and Prestige Biopharma will be participating as a drug substance (DS) manufacturer.The Sputnik V vaccine was developed at the Gamaleya National Research Centre for Epidemiology and Microbiology in Russia and it has been authorized in approximately 60 countries.Prestige Biopharma vaccine center commenced construction last month with the aim of producing vaccines and therapeutics for COVID-19 and to prepare for future pandemics. The vaccine center’s test operation is expected to commence in August, and aims to start full production of 2,000 liters of vaccine DS per batch from September this year with the consortium’s technology transfer.Prestige Biopharma will be using Prestige Biologics’ ALITA, the world’s first smart factory system designed based on digital artificial intelligence, which will contribute to reducing process error and human error. This smart factory’s ‘single-use bag’ system will enable mass production of vaccine in the short-term.Dr. Lisa S. Park, CEO of Prestige Biopharma, commented: “We are pleased to contribute to defeating the pandemic and also feel a heavy responsibility of joining the world’s first approved COVID-19 vaccine, Sputnik V’s manufacturing consortium,” and “With the start of this project, we will ultimately aim to develop our own vaccine products to meet the demands of vaccines for future pandemics.”

SINGAPORE, April 15, 2021 – Prestige BioPharma and Pharmapark LLC today announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Bevacizumab biosimilar in the Russian Federation.Prestige’s Bevacizumab (HD204) is a mAb biosimilar to Roche’s Avastin®, an inhibitor of vascular endothelial growth factor (VEGF), which is used in combination with other therapies to treat patients with multiple forms of cancer including metastatic colorectal cancer, advanced non-small-cell lung cancer, advanced kidney cancer, certain types of epithelial cancers and cancers of the cervix. HD204 is currently in Phase III clinical development with active recruitment ongoing within the pivotal efficacy and safety trial SAMSON-II. Positive results were previously reported from the Phase I clinical trial (SAMSON-I) which evaluated the pharmacokinetics, safety and immunogenicity of HD204 to Avastin®.The partnership arrangement includes the exclusive rights for Pharmapark to commercialize the Bevacizumab biosimilar in the Russian Federation, leveraging the company’s strong sales and marketing capabilities and experience in successfully bringing new biosimilars to market. Whilst the terms of the deal are not being disclosed, Prestige BioPharma will assume responsibility for product commercial supply out of its manufacturing facilities in Osong, Korea, while Pharmapark will be responsible for local registration, sales and marketing in the Russian Federation with the option to manufacture the product in Russian Federation in line with the Russian import substitution strategy.This agreement expands upon the existing collaboration between Prestige BioPharma and Pharmapark LLC with the companies signing a license agreement in July 2019 for Prestige BioPharma’s Herceptin® biosimilar.Dr. Lisa S. Park, CEO of Prestige BioPharma, commented: “We are very pleased to further extend our partnership with Pharmapark to commercialize our second biosimilar program in the Russian Federation. We are excited to bring another high-quality product to this key market with the ultimate goal to make the product available globally.”Vyacheslav Lebedyansky, CEO of Pharmapark, commented: “This extension to our existing partnership with Prestige BioPharma is another important milestone for Pharmapark allowing our company to bring vital and affordable medicines to Russian population in line with the Russian Pharma-2030 strategy. Bevacizumab biosimilar candidate will be an excellent addition to our growing biosimilar portfolio.”

SINGAPORE, April 7, 2021 – Prestige Biopharma Limited, specializing in the development of antibody therapeutics, announced on April 7, 2021 that test operation of some of the facilities in its vaccine center is expected to begin in as early as August this year. The company is slated to complete a production system validation and will be ready for production by the end of this year. The vaccine center has commenced construction last month and has begun to procure equipment for the facility.Prestige Biopharma has been planning for business expansion into development of vaccine and therapeutics for future pandemics since the COVID-19 outbreak. The vaccine center has started as part of this plan.Prestige Biopharma will use Prestige Biologics’ contract engineering organization service to build the vaccine center with “ALITA,” a smart factory construction method. With this service, the company aims to start full production of COVID-19 vaccine by the end of the year.In the meantime, the company is slated to expand its investor communication channels to provide the consistent and clear information for shareholder concerns about the company’s business issues and plan. The company is also considering to repurchase shares to drive shareholder value and stock price if necessary.Dr. Lisa S. Park, CEO of Prestige Biopharma, commented: “We sincerely appreciate the shareholders’ interest and support during this pandemic and will make every effort to take responsibility as a listed company and enhance the company’s market value by business expansion into vaccine industry with the new vaccine production center.”

SINGAPORE, March 31, 2021 – Prestige Biopharma Ltd., specializing in the development of antibody therapeutics, announced on March 31, 2021 that the company has commenced construction of a vaccine production center.Prestige Biopharma had a groundbreaking ceremony in Prestige Biologics’ Campus 2 site and officially began construction on its new vaccine production center.Prestige Biopharma’s vaccine production center with a total area of approximately 8,500 square meters will have a maximum production capacity to produce 100,000 liters. The center also will be designed to be applied to various manufacturing process and maximize efficiency utilizing Prestige Biologics’ customized engineering technology.The company is slated to complete a production system validation and will be ready for production by the end of this year. In addition to that, PBP will make every effort to meet the demands of vaccines for any infectious disease, starting with COVID-19 vaccine production.Dr. Lisa S. Park, CEO of Prestige Biopharma, commented: “COVID-19 vaccine production needs to be ramped up to achieve ‘herd immunity’ and we will also need a vaccine to tackle new variants of the COVID-19 virus,” and “Hopefully this global-scale vaccine manufacturing center will contribute to generating the company’s new revenue sources and at the same time to assist in defeating the pandemic as well.”

SINGAPORE, February 24, 2021 – Prestige Biopharma Ltd., specializing in the development of new antibody therapeutics and biosimilars, officially announced on February 24, 2021 that their stock symbol will be changed from ‘PBPharma’ to ‘PRESTIGE BIOPHARMA’ as of March 2, 2021.This change aims “to standardize our stock symbol with Prestige Biologics Co., Ltd. scheduled to be listed on KOSDAQ next month and provide a clear understanding of each company’s business areas”, an official at Prestige Biopharm said. The company added that “we sincerely appreciate the investors’ interest and will make every effort to take responsibility as a listed company and add long-term value to the company by focusing on the development of biosimilars and new antibody therapeutics”.Prestige Biopharm was listed on the KOSPI market on February 5, 2021, and ‘PRESTIGE BIOPHARMA’ will be indicated as its stock symbol from March 2, 2021. The affiliated manufacturing company, Prestige Biologics Co., Ltd. is also slated to be listed on KOSDAQ with its symbol name, ‘PRESTIGE BIOLOGICS’.Prestige Biopharm is a Singapore based biopharmaceutical company developing eight biosimilars and two new antibody therapeutics and its IPO fund will be invested in R&D facilities and penetrating the global pharmaceutical market. The company is currently working on the marketing authorization approval of its Trastuzumab biosimilar to Herceptin (HD201), the marketing authorization application of its Bevacizumab biosimilar to Avastin (HD204) and the clinical development of an innovative anti-PAUF mAb (PBP1510) and an Adalimumab biosimilar (PBP1502).

SINGAPORE, February 22, 2021 – Prestige Biopharma Limited., specializing in the development of new antibody therapeutics, has appointed a former Pfizer researcher, Dr. Deborah Moshinsky as research director at Prestige Biopharma Advanced Research Centre (ARC) in Boston, USA, that is scheduled to be opened this year.Dr. Moshinsky is a biologics expert with a doctoral degree from MIT and has twenty years of R&D experience in global pharmaceuticals such as Pfizer and Novartis. She has been contributing to PBP’s biosimilar & new antibody drug development as a scientific advisor for the last few years.Dr. Moshinsky will lead in essential research areas of antibody therapeutics like bioanalysis, Good Laboratory Practice (GLP) standard and discovery of new antibody therapeutics. ARC will also be the research hub for future infectious diseases like mutated COVID-19 virus variants.Boston is known as the largest bio cluster in USA and the thousands of companies in the cluster are generating seventy-four thousand new jobs and two billion dollars of economic value. Boston is also home to major universities and venture companies, including global pharmaceutical & biotech companies and research institutes.Dr. Lisa S. Park, CEO of Prestige Biopharma, commented: “ARC will be a base camp for PBP to leap to a global pharma company and Dr. Deborah’s team will help the company to speed up its R&D on biosimilar and antibody therapeutics.”